Martin Gerard McCabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Martin Gerard McCabe has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Nathalie Gaspar
Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
7 shared publications - Stefan M. Pfister
Hopp Children's Cancer Center Heidelberg (KiTZ)
7 shared publications V. Peter Collins
Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK
7 shared publications- Dafydd Gareth Evans
Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK
6 shared publications - Michael D. Taylor
Texas Children’s Hospital, Baylor College of Medicine , Houston, Texas
6 shared publications Paul A. Northcott
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69121 Heidelberg, Germany
6 shared publications
Latest Publications
- 4 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations
PURPOSE: Ewing sarcoma is an aggressive bone cancer driven by FET::ETS fusions, with few recurrent secondary genomic alterations (most commonly involving STAG2 , TP53 , and CDKN2A ) and copy-number variants. Currently, diagnosis relies exclusively on tumor biopsies and imaging, and despite a well-defined genomic landscape, risk stratification remains based solely on clinicoradiologic parameters. Furthermore, tumor evolution and intrapatient heterogeneity remain poorly characterized, and prospective evidence supporting molecular risk stratification is limited. MATERIALS AND METHODS: We prospectively integrated serial circulating tumor DNA (ctDNA) sampling into the first-line phase II/III Euro Ewing 2012 (EE2012) and CombinaiR3 trials, complemented by relapse studies. Across 347 patients, 991 blood, tumor, and bone marrow samples were profiled using custom targeted sequencing and shallow whole-genome sequencing to enable integrated biologic characterization and clinical correlative analyses. RESULTS: ctDNA recapitulated established Ewing sarcoma genomic landscapes while also revealing intrapatient tumor heterogeneity when compared with matched tumor biopsy profiles. Blood and bone marrow plasma profiles were highly concordant. Longitudinal sampling identified selection of TP53 -altered clones at relapse. Clinically, detection of TP53 and/or STAG2 loss-of-function mutations and/or CDKN2A focal deletions in ctDNA at diagnosis predicted poor outcomes and, in a multivariable model adjusting for metastatic status, tumor volume, age, and treatment, defined an independent molecular high-risk subgroup with inferior event-free survival (hazard ratio [HR], 3.6 [95% CI, 2.2 to 5.8], P < .001) and overall survival (HR, 4.3 [95% CI, 2.5 to 7.3], P < .001) in EE2012 patients. CONCLUSION: Prospective, trial-integrated ctDNA profiling provides comprehensive molecular characterization, reveals clinically relevant heterogeneity and clonal evolution, and identifies an independent molecular high-risk subgroup at diagnosis, supporting ctDNA-guided risk stratification in Ewing sarcoma.
- 4 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53 , STAG2 , and CDKN2A Alterations
PURPOSE: Ewing sarcoma is an aggressive bone cancer driven by FET::ETS fusions, with few recurrent secondary genomic alterations (most commonly involving STAG2 , TP53 , and CDKN2A ) and copy-number variants. Currently, diagnosis relies exclusively on tumor biopsies and imaging, and despite a well-defined genomic landscape, risk stratification remains based solely on clinicoradiologic parameters. Furthermore, tumor evolution and intrapatient heterogeneity remain poorly characterized, and prospective evidence supporting molecular risk stratification is limited. MATERIALS AND METHODS: We prospectively integrated serial circulating tumor DNA (ctDNA) sampling into the first-line phase II/III Euro Ewing 2012 (EE2012) and CombinaiR3 trials, complemented by relapse studies. Across 347 patients, 991 blood, tumor, and bone marrow samples were profiled using custom targeted sequencing and shallow whole-genome sequencing to enable integrated biologic characterization and clinical correlative analyses. RESULTS: ctDNA recapitulated established Ewing sarcoma genomic landscapes while also revealing intrapatient tumor heterogeneity when compared with matched tumor biopsy profiles. Blood and bone marrow plasma profiles were highly concordant. Longitudinal sampling identified selection of TP53 -altered clones at relapse. Clinically, detection of TP53 and/or STAG2 loss-of-function mutations and/or CDKN2A focal deletions in ctDNA at diagnosis predicted poor outcomes and, in a multivariable model adjusting for metastatic status, tumor volume, age, and treatment, defined an independent molecular high-risk subgroup with inferior event-free survival (hazard ratio [HR], 3.6 [95% CI, 2.2 to 5.8], P < .001) and overall survival (HR, 4.3 [95% CI, 2.5 to 7.3], P < .001) in EE2012 patients. CONCLUSION: Prospective, trial-integrated ctDNA profiling provides comprehensive molecular characterization, reveals clinically relevant heterogeneity and clonal evolution, and identifies an independent molecular high-risk subgroup at diagnosis, supporting ctDNA-guided risk stratification in Ewing sarcoma.
- Open Access
- 2 October 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 248
Recent trends in childhood, teenage and young adult cancer incidence in England (2001–2020)
- 2 October 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 248
Open AccessRecent trends in childhood, teenage and young adult cancer incidence in England (2001–2020)
- Open Access
- 18 August 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-16
Paediatric therapeutic development workshop on osteosarcoma
The fourth Paediatric Therapeutic Development Workshop focused on osteosarcoma, the most common primary bone cancer in children and young adults. Current treatment of osteosarcoma comprises surgery and chemotherapy. Outcome has shown very little improvement over the last four decades and there are substantial unmet needs including improving survival, especially in metastatic or relapsed disease, and reducing treatment toxicity. There is a lack of new therapeutics in osteosarcoma, with the evaluation of new treatments challenged by complex biology and variation in chemotherapy standard of care regimens. An antibody-drug conjugate (ADC) targeting LRRC15 with an osteosarcoma-relevant payload is a promising therapeutic approach. Small molecule inhibitors and degraders targeting SMARCAL1 should be considered as a very high priority, as it is a target applicable to several high unmet need malignancies. Preclinical evaluation of KIF18A in osteosarcoma models is required. An early phase study of an eIF4A1 inhibitor is warranted. Further preclinical validation of RUNX2 using PROTACs or ADCs is required. Targeting MYC, either indirectly or directly is a high priority. Osteosarcomas have significant genomic instability and impaired DNA repair mechanisms and efforts are ongoing to exploit this vulnerability therapeutically. The goal is that these therapeutic developments will improve survival for patients with osteosarcoma.
- 18 August 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-16
Open AccessPaediatric therapeutic development workshop on osteosarcoma
The fourth Paediatric Therapeutic Development Workshop focused on osteosarcoma, the most common primary bone cancer in children and young adults. Current treatment of osteosarcoma comprises surgery and chemotherapy. Outcome has shown very little improvement over the last four decades and there are substantial unmet needs including improving survival, especially in metastatic or relapsed disease, and reducing treatment toxicity. There is a lack of new therapeutics in osteosarcoma, with the evaluation of new treatments challenged by complex biology and variation in chemotherapy standard of care regimens. An antibody-drug conjugate (ADC) targeting LRRC15 with an osteosarcoma-relevant payload is a promising therapeutic approach. Small molecule inhibitors and degraders targeting SMARCAL1 should be considered as a very high priority, as it is a target applicable to several high unmet need malignancies. Preclinical evaluation of KIF18A in osteosarcoma models is required. An early phase study of an eIF4A1 inhibitor is warranted. Further preclinical validation of RUNX2 using PROTACs or ADCs is required. Targeting MYC, either indirectly or directly is a high priority. Osteosarcomas have significant genomic instability and impaired DNA repair mechanisms and efforts are ongoing to exploit this vulnerability therapeutically. The goal is that these therapeutic developments will improve survival for patients with osteosarcoma.
- 8 August 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 246, 116981
Incidence and survival of primary bone sarcoma diagnosed in England between 1996 and 2020; An analysis from the National Disease Registration Service
- 8 August 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 246, 116981
Incidence and survival of primary bone sarcoma diagnosed in England between 1996 and 2020; An analysis from the National Disease Registration Service
- 31 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study
PURPOSE: Euro-EWING99 study was a large, international, prospective study recruiting patients with Ewing sarcoma (EWS) between 1999 and 2015. It assessed three different clinical questions through randomized trials. We report here the characteristics and outcomes of all patients. METHODS: Patients younger than 50 years with EWS were included in the study. They received induction chemotherapy (six courses of vincristine [day 1], ifosfamide [day 1-3], doxorubicin [day 1-3], and etoposide [day 1-3; VIDE], administered every 3 weeks), local therapy (surgery/radiotherapy), and different consolidation treatments according to clinical risk group and trial. The objectives of the study were to describe the entire cohort according to the initial staging group, to describe the survival outcomes (overall survival [OS]; progression-free survival [PFS]; and local control), and to evaluate prognostic factors associated with OS and PFS. RESULTS: Three thousand three hundred ninety-five patients were included in the study, including 2,267 with a localized disease, 614 with pleuropulmonary metastases, and 514 with extrapulmonary metastases. Ninety-eight percent of patients received ≥4 neoadjuvant VIDE courses. The modalities of local treatment and consolidation therapy differed among the three staging groups. With a median follow-up of 7.2 years, PFS of the entire cohort was 60.2% and 55.4% at 3 and 5 years, respectively. OS was 72.6% and 64.6% at 3 and 5 years, respectively. In addition to metastatic status at diagnosis, main prognostic factors included patient age, tumor volume, and histologic response both for PFS and OS, independent of metastatic status. CONCLUSION: To our knowledge, this study is the largest published series of patients with EWS and may serve as a landmark paper for EWS. It confirms the major prognostic value of the complete histologic response after neoadjuvant therapy.
- 31 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study
PURPOSE: Euro-EWING99 study was a large, international, prospective study recruiting patients with Ewing sarcoma (EWS) between 1999 and 2015. It assessed three different clinical questions through randomized trials. We report here the characteristics and outcomes of all patients. METHODS: Patients younger than 50 years with EWS were included in the study. They received induction chemotherapy (six courses of vincristine [day 1], ifosfamide [day 1-3], doxorubicin [day 1-3], and etoposide [day 1-3; VIDE], administered every 3 weeks), local therapy (surgery/radiotherapy), and different consolidation treatments according to clinical risk group and trial. The objectives of the study were to describe the entire cohort according to the initial staging group, to describe the survival outcomes (overall survival [OS]; progression-free survival [PFS]; and local control), and to evaluate prognostic factors associated with OS and PFS. RESULTS: Three thousand three hundred ninety-five patients were included in the study, including 2,267 with a localized disease, 614 with pleuropulmonary metastases, and 514 with extrapulmonary metastases. Ninety-eight percent of patients received ≥4 neoadjuvant VIDE courses. The modalities of local treatment and consolidation therapy differed among the three staging groups. With a median follow-up of 7.2 years, PFS of the entire cohort was 60.2% and 55.4% at 3 and 5 years, respectively. OS was 72.6% and 64.6% at 3 and 5 years, respectively. In addition to metastatic status at diagnosis, main prognostic factors included patient age, tumor volume, and histologic response both for PFS and OS, independent of metastatic status. CONCLUSION: To our knowledge, this study is the largest published series of patients with EWS and may serve as a landmark paper for EWS. It confirms the major prognostic value of the complete histologic response after neoadjuvant therapy.
- 18 April 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 240, 116751
From bench to byte: A UK perspective on data-driven cancer research
- 18 April 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 240, 116751
From bench to byte: A UK perspective on data-driven cancer research
- Open Access
- 10 April 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (4) , 211
Mixed-Methods Evaluation of the Delivery of Cancer Care to Teenagers and Young Adults in England and Wales: BRIGHTLIGHT_2021
Background: Healthcare policy in the United Kingdom recognizes that teenagers and young adults (TYAs: 16–24 years at diagnosis) require specialist care. In England, Principal Treatment Centers (PTCs) exist, delivering enhanced care exclusively within the PTC or as ‘joint care’ with designated hospitals (DHs). Central to this is the TYA multidisciplinary team (MDT) and an outreach model coordinating care between hospitals. We previously reported similar outcomes regardless of care location. Aims: To compare TYA experiences of care with healthcare professionals’ perspectives of the service they deliver. Methods: Mixed methods across England and Wales were used. The TYA-MDT identified TYAs who then received a postal invite to a cross-sectional survey capturing experiences of places of care, treatment, healthcare professional support (HCP), mental health, sexuality/fertility, clinical trials and care coordination. Comparisons were made based on exposure to care in a specialist TYA environment within 6 months of diagnosis: all-TYA-PTC (all care in the TYA-PTC, n = 70, 28%), no-TYA-PTC (no care in the TYA-PTC (n = 87, 35%): care delivered in a children/adult unit only), and joint care (care in a TYA-PTC and in a children’s/adult unit, n = 91, 36%). HCP perspectives were captured by rapid ethnography. Results: A total of 250/1056 (24%) TYAs participated. Overall, 200 (80%) rated their teams as excellent/good for helping them prepare for treatment. No evidence of significant differences existed between categories of care for proportions receiving support from key TYA-related professionals: TYA cancer nurse specialists (all-TYA-PTC n = 58, 91%; joint care n = 71, 88%; no-TYA-PTC n = 64, 82%) and social workers (all-TYA-PTC n = 30, 55%; joint care n = 36, 48%; no-TYA-PTC n = 28, 38%). A trend of diminishing support from youth support co-coordinators existed (all-TYA-PTC 63%; joint care 49%; no-TYA-PTC 40%, p = 0.069). This may explain why few differences in patient experiences existed across categories of care. Forty-nine HCPs participated. They were more critical in their interpretation of care, highlighting inequity in resources and challenges in some pathways and coordination. Conclusions: Similar access to age-appropriate support across care settings is likely to reflect recruitment methods. When TYAs are known to the MDT, age-appropriate care can be mobilized beyond TYA units, which could explain the equitable outcomes observed across different care locations in young people who responded to the survey. Nevertheless, gaps persist in communication and coordination, particularly within joint care models, and in the involvement of allied health professionals such as dieticians and physiotherapists, whose input is essential for rehabilitation and return to normal life. Strengthening these areas will require continued investment in workforce capacity and digital infrastructure to support genuinely coordinated, developmentally appropriate TYA cancer care.
- 10 April 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (4) , 211
Open AccessMixed-Methods Evaluation of the Delivery of Cancer Care to Teenagers and Young Adults in England and Wales: BRIGHTLIGHT_2021
Background: Healthcare policy in the United Kingdom recognizes that teenagers and young adults (TYAs: 16–24 years at diagnosis) require specialist care. In England, Principal Treatment Centers (PTCs) exist, delivering enhanced care exclusively within the PTC or as ‘joint care’ with designated hospitals (DHs). Central to this is the TYA multidisciplinary team (MDT) and an outreach model coordinating care between hospitals. We previously reported similar outcomes regardless of care location. Aims: To compare TYA experiences of care with healthcare professionals’ perspectives of the service they deliver. Methods: Mixed methods across England and Wales were used. The TYA-MDT identified TYAs who then received a postal invite to a cross-sectional survey capturing experiences of places of care, treatment, healthcare professional support (HCP), mental health, sexuality/fertility, clinical trials and care coordination. Comparisons were made based on exposure to care in a specialist TYA environment within 6 months of diagnosis: all-TYA-PTC (all care in the TYA-PTC, n = 70, 28%), no-TYA-PTC (no care in the TYA-PTC (n = 87, 35%): care delivered in a children/adult unit only), and joint care (care in a TYA-PTC and in a children’s/adult unit, n = 91, 36%). HCP perspectives were captured by rapid ethnography. Results: A total of 250/1056 (24%) TYAs participated. Overall, 200 (80%) rated their teams as excellent/good for helping them prepare for treatment. No evidence of significant differences existed between categories of care for proportions receiving support from key TYA-related professionals: TYA cancer nurse specialists (all-TYA-PTC n = 58, 91%; joint care n = 71, 88%; no-TYA-PTC n = 64, 82%) and social workers (all-TYA-PTC n = 30, 55%; joint care n = 36, 48%; no-TYA-PTC n = 28, 38%). A trend of diminishing support from youth support co-coordinators existed (all-TYA-PTC 63%; joint care 49%; no-TYA-PTC 40%, p = 0.069). This may explain why few differences in patient experiences existed across categories of care. Forty-nine HCPs participated. They were more critical in their interpretation of care, highlighting inequity in resources and challenges in some pathways and coordination. Conclusions: Similar access to age-appropriate support across care settings is likely to reflect recruitment methods. When TYAs are known to the MDT, age-appropriate care can be mobilized beyond TYA units, which could explain the equitable outcomes observed across different care locations in young people who responded to the survey. Nevertheless, gaps persist in communication and coordination, particularly within joint care models, and in the involvement of allied health professionals such as dieticians and physiotherapists, whose input is essential for rehabilitation and return to normal life. Strengthening these areas will require continued investment in workforce capacity and digital infrastructure to support genuinely coordinated, developmentally appropriate TYA cancer care.
- Open Access
- 6 March 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (4) , 1342-1357
Cell-free DNA methylome and fragmentome analysis for relapse monitoring of Ewing sarcoma
Liquid biopsies and cell-free DNA (cfDNA) offer minimally invasive methods for the diagnosis and monitoring of Ewing Sarcoma (EwS). EwS have a low tumour mutational burden and their detection with plasma cfDNA is challenging. We hypothesised that analysing the cfDNA methylome and fragmentome could enhance sensitivity for detecting EwS and identifying disease recurrence. Using T7-MBD-seq, we conducted whole-genome and methylome sequencing of cfDNA from 87 serial samples of 23 patients with EwS and 3 patients with CIC-rearranged sarcoma (CIC). With EwingSign, a new machine learning model, we identified EwS or CIC in a test set for 11 out of 16 patients at diagnosis and 15 out of 18 clinically confirmed relapse events. 0 out of 24 non-cancer controls (NCC) were detected positive with EwingSign. When combined with global and regional fragmentome analysis, all 18 relapse cases were detected, with 15/18 detected by 2 or more modalities, and 1 out of 24 NCC was detected by one modality. These findings indicate that cfDNA methylome and fragmentome analysis, if validated in a larger cohort, could improve disease detection, monitoring and relapse identification in patients with EwS.
- 6 March 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (4) , 1342-1357
Open AccessCell-free DNA methylome and fragmentome analysis for relapse monitoring of Ewing sarcoma
Liquid biopsies and cell-free DNA (cfDNA) offer minimally invasive methods for the diagnosis and monitoring of Ewing Sarcoma (EwS). EwS have a low tumour mutational burden and their detection with plasma cfDNA is challenging. We hypothesised that analysing the cfDNA methylome and fragmentome could enhance sensitivity for detecting EwS and identifying disease recurrence. Using T7-MBD-seq, we conducted whole-genome and methylome sequencing of cfDNA from 87 serial samples of 23 patients with EwS and 3 patients with CIC-rearranged sarcoma (CIC). With EwingSign, a new machine learning model, we identified EwS or CIC in a test set for 11 out of 16 patients at diagnosis and 15 out of 18 clinically confirmed relapse events. 0 out of 24 non-cancer controls (NCC) were detected positive with EwingSign. When combined with global and regional fragmentome analysis, all 18 relapse cases were detected, with 15/18 detected by 2 or more modalities, and 1 out of 24 NCC was detected by one modality. These findings indicate that cfDNA methylome and fragmentome analysis, if validated in a larger cohort, could improve disease detection, monitoring and relapse identification in patients with EwS.